RP1/Nivolumab Combo Produces Deep, Durable Responses in Melanoma and Other Skin Cancers

Source: Onc Live, April 2022

The combination of the oncolytic vaccine vusolimogene oderparepvec (RP1) and nivolumab (Opdivo) continued to drive encouraging responses with acceptable tolerability in patients with melanoma and other skin cancers, according to updated findings from the phase 2 IGNYTE trial (NCT03767348).1

In the 8 patients with cutaneous melanoma who were naïve to PD-1 inhibition, the objective response rate (ORR) achieved with the doublet continued to be 62.5%; this included a complete response (CR) rate of 37.5% and a partial response (PR) rate of 25.0%. Among the 16 patients with cutaneous disease in whom checkpoint therapy had previously failed, the ORR achieved with the regimen increased from 31.3% in June 2021 to 37.5%; in this subset, the CR rate was 12.5% and the PR rate was 25.0%.

READ THE ORIGINAL FULL ARTICLE